XXXXXXXX XXXXXX V PŘENESENÉ XXXXXXXXX (XX) x. 1062/2014
xx xxx 4. xxxxx 2014,
xxxxxxxx xx xxxxxxxxxx programu systematického xxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxx x xxxxxxxxxx přípravcích, které xxxx uvedeny v xxxxxxxx Evropského xxxxxxxxxx x Xxxx (XX) č. 528/2012
(Xxxx x xxxxxxxx xxx XXX)
XXXXXXXX KOMISE,
s ohledem na Xxxxxxx o fungování Xxxxxxxx xxxx,
x xxxxxxx na xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (EU) x. 528/2012 xx xxx 22. xxxxxx 2012 x xxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx x jejich xxxxxxxxx (1), x zejména xx xx. 89 xxxx. 1 xxxxx xxxxxxxxxxx uvedeného nařízení,
xxxxxxxx x těmto důvodům:
|
(1) |
Nařízení Xxxxxx (XX) x. 1451/2007 (2) xxxxxxx xxxxxxxxx pravidla xxx program xxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxxx xxxxx (xxxx xxx „xxxxxxx přezkumu“), xxxxx xxx xxxxxxx v souladu x xx. 16 xxxx. 2 směrnice Xxxxxxxxxx xxxxxxxxxx a Rady 98/8/XX (3). Protože xxxx xxxxxxxx xxxx xxxxxxx x xxxxxxxxx nařízením (EU) x. 528/2012, měla by xxx xxxxxxxxx pravidla xxx pokračování xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx. |
|
(2) |
Je xxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxxx x xxxx xxxxxxxxx, xxxxx mohou xxx xxxxxxxx na trh x xxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxxxx článku 89 nařízení (XX) x. 528/2012 x xxxxxxxx xxxxxxxxxxxxxx předpisů. Xxxx xx tomu být x x xxxxxxx xxxxxxxxx xxxxxx látky x xxxx xxxxxxxxx, xxxxx jsou xxxxxxxxx x programu xxxxxxxx. |
|
(3) |
Xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxx potraviny x xxxxxx xxxxx článku 6 xxxxxxxx (XX) x. 1451/2007, xxx nevztahuje xx xx xxx xxxxxxx xxx potraviny a krmiva xxxxxxx x xx. 2 xxxx. 5 xxxx. x) nařízení (XX) x. 528/2012, xxxx xx xxx xxxxxx xxxxx, xxxxx obsahuje, xxxxxxxxx x xxxxxxxx xxxxxxxx xxx xxxxxxxxx xxx přípravku. X xxxxxxxx vnitrostátních xxxxxxxx xx xxxx být xxxxxx dodávání xx xxx x xxxxxxxxx umožněno až xx xxxxxxxx xxxxxxxxx hodnocení. Xxxxxx xxxxxxxxxxx xxxxxxxxxx xx xxx vymezit, xxxxx přípravky xxxxxx xxxxxxxxxx xxxxxxx. Totéž xx xxxx xxxxxx x xxxxxxxxx, kdy neoznámení xxxxxxxxx xxxxxx xxxxx x xxxx xxxxxxxxx vyplynulo x nové xxxxxxxx xxxx přípravků x xxxxxxxx (XX) x. 528/2012 xxxxxx xxxxxxxx xxxxxxx xx xxxxxxxx 98/8/XX xxxx xx řádně xxxxxxxxxx xxxxxxxxxxx Xxxxxx xxxxxxxx x xxxxxxx x xx. 3 xxxx. 3 xxxxxxxx (EU) č. 528/2012, xxxxxxxxxxx (xxxxxxxxx rozhodnutím xx xxxx X-420/10 (4)) xxxx xxxxxxxxx xxxxxx Xxxxxx xx xxxxxxxxxxx xxxxxx xxxxxxxxx států, xxxxx xx xxxxxxxx xxxxxxx. |
|
(4) |
Xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxx, xxxxx xxx xxxx xxxxxxxx xx xxxxxxxx xxxxxxxx, x xxxx xxxxx xxxxxxx nebo xx x ní xxxxxx, xxxxx současně xx xxxxxxxxx xxxxxx xxxxxxxxxx přípravku x xxxxxxxx xxxxx xxxxxxxx, xxxx xx xxx x xxxxx xxxxxxxx státě xxxxxxx x xxxxxxxx na trh xxxxxxxx na xxxx xxxxxxxxxxxx, za xxxxxxxx xxxxxxxx x xx omezenou xxxx. |
|
(5) |
X zájmu xxxxxxxxxxx x xxxxxxxxxxxx by xxx xxx postup xxxxxxxxx xxxxxxxx xxxxx x xxxxxxxx xxxxxxxx xx xxxxx xxxxxxxxxx xxxxxxx xxxxxxx x xxxxxxxx xxxxxxxxxx xxx xxxxxxx xxxxxxxxxx xxxxx xxxxxx 7 xxxxxxxx (XX) x. 528/2012 nebo xxxxx xxxxxxxxxxx xxxxxxxx Xxxxxx (XX) x. 88/2014 (5). |
|
(6) |
Pro xxxxx, které xxxxxxx xxxxxxxx xxxxxxxxx xxxx xxxxxxxx xxx xxxxxxx, xx měl xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx návrh harmonizované xxxxxxxxxxx a označení látky xxxxx čl. 37 odst. 1 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (ES) x. 1272/2008 (6), xxxxx xxx o xxxxxxxxx xxxxxxxxxx vzbuzující xxxxx, a zároveň by xxxx xxx zachováno xxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx xxxxxxxx xx xxxxxx xxxx xxxxx xxxxxxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxxxxxx xxxxx xx xxx také xxxxxxxxxxx agenturu v xxxxxxx látek, které xx xxxxxxxxx kritéria xxx látky xxxxxxxxxxxx, xxxxxxxxxxxxxxx xx xxxxxxx, nebo xxxxx, xxxxx xx xxxxx xxx považovány xx látky x xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx. |
|
(7) |
Xxx xxxx xxxxxxxxx, xx xxxxxxx xxxxxxxx xxxx dokončen xx xxxxxxxx xxxx uvedeného x xx. 89 xxxx. 1 nařízení (XX) č. 528/2012, xxxx xx xx hodnocení xxxxxx xx xxxxxxxxx xxxxxx látky a typu xxxxxxxxx, x xxxxx xxxx xxxxxxxxx údaje xxxxxxxxxx xx xxxxxxx stanovených x xxxxxxxx (ES) č. 1451/2007 xxxx x xxxxx nařízení. Xxxxx xxxx xx xx xxxx stanovit xxxxxx xxxxx xxx xxxxxxxxx xxxxxxxxx, xxxxxxx xx xx xxxx xxxx x xxxxx xxxxxxx, xx xxxxxxx xx xxxxx xxx xxxxxxxxx xxxx xxx xxx xxxx xxxxxxxxx xxxxxx xxxx. |
|
(8) |
Xxxxxxx xxxxxxxx xx xxxxxxx X xxxxxxxxx 7 xxxxxxxx (XX) č. 528/2012 xxxxx xxxxxx xxxxxxxxx žádné xxxxxxxxx na xxxxx. Xx proto vhodné x této fázi xxxxxx žádosti o zařazení xx xxxxxxx xxxxxxx xx kategorie 1, 2, 3, 4, 5 xxxx 6. |
|
(9) |
Xxx xxxxxx na čl. 90 xxxx. 2 xxxxxxxx (EU) č. 528/2012 xxxxxxx z článku 91 xxxxxxxxx nařízení, xx xxxxxxxx uvedená x xxxxxx 10 xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxxx xxx následné xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxxxx xxxxxxxxx. Xx xxxxx xxxxxx xxxxx látky xxxxxxxxx tato kritéria xx xxxxx xxxxxxxxxxx účinných xxxxx. |
|
(10) |
Xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xx měl xxx xxxxxxx se xx xxxxxxxx xxxxxx xxxxxxxx ke xxxxxxxxxxx xxxxxxxxxxx xxxx xxx xxxxxxxx xx xxxxxxxxxxx, xx xxxxx tomu xxxxxxx ke zpoždění xxxxxxxxx z důvodu xxxxxxxxx xxxxxxxx x údajům, xxxxxxx xxxxx xx xxxxxxxxxxx účastník musel xxxxxxxxx xxxxx znovu. |
|
(11) |
Xxxxxxx xx účast x xxxxxxxx xxxxxxxx xxxxxxxxxx, xxxx xx být xxxxxxxxxx xxxxxxxx xx ní xxxxxxxxx. Pokud x xxxx xxxxx, xxxx xx xxx potenciální xxxxxxxxx xxxxxxx převzít xxxxxxx, nebylo-li xxxx xxxxxxxx xxxxxxx již xxxxxx, xxxxx xxx xxxxxxx xx zpoždění xxxxxxxx xxxxxxxx, a xxxxxxxx-xx xxxxxxxx již xxxxxxxx na svém xxxxxxxxxx. |
|
(12) |
Xxxxx xx xxx xxxxxxxxx účinné látky xxxxx, xx xxxxxxxx oficiálně xxxxxxxx xx xxxxxxxx xxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxx, x x xxxxxxxxx xxxxx xxxxxxx xxxxxx xxxxxxx xxxxxxxx oficiálně xxxxxxxx xxxxx, xxxx by xxx xxxxx xxxx xxxxx v průběhu xxxxxxxxx xxxxx xxxxxxxxx x xxxxxxx xxxxx xxxxxx, aby xxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx. |
|
(13) |
Xxxxxxx xxxxx xxxxxxxx xx xxxxxxxx xxxxxxxx nejsou x době xxxxxxx xxxxxx nařízení podporovány xxxxxx xxxxxxxxxx. Totéž xx týká určitých xxxxxxxxxxxxx, ačkoli xxxxx xx. 4 odst. 4 xxxxxxxx (XX) č. 528/2012 xxxx xxxxxxxxx xxxxx schválit, xxxxx tak xxxx xxxxxxxx xxxxxxxxx. X xxxxxxxxx xxxxx x xxxxxxxxxxxxx xx měly xxx xxxxx xxxxxxx xxxxxxx xxxxx, protože xxxxx by xxxx xxxxx x xxxxxxxxxxxxx xxxxxx xxx x xxxxxxxx xxxxxxxx vyloučeny. |
|
(14) |
Xxx bylo xxxxxxxxx, xx xxxxx xxxxx xxxxxxxxx v xxxxxxxx neoprávněně xxx xx něj xxxxxx xxxxxxxx, xxxx xx xxxxxxxx xxxx xxxxxxxxxxx, xxxx xx xxxxxxxx xxxxx, která xxxxx xxxxxx xxxxxxxxx, x xxxxxxxx xxxx její xxxxxxxx podléhat oznamování xxxxxxxxxx údajů x xx, |
XXXXXXX XXXX XXXXXXXX:
XXXXXXXX 1
PŘEDMĚT X XXXXXXXX
Xxxxxx 1
Předmět
Toto xxxxxxxx xxxxxxx xxxxxxxx xxx xxxxxxxxx pracovního programu xxxxxxxxxxxxxx xxxxxxxx všech xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx v článku 89 nařízení (XX) x.&xxxx;528/2012.
Xxxxxx 2
Xxxxxxxx
Pro xxxxx xxxxxx nařízení xx xxxxxxx xxxx xxxxxxxx:
|
x) |
„xxxxxxxxxxx x xxxxxxxxxxx“ se xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx podle xx. 9 xxxx. 1 xxxx. x) xxxxxxxx (XX) x. 528/2012 nebo xx. 89 odst. 1 xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx, xxxx xxxxxxxxx nezařadit xx xxxxxxx I nebo IA xxxxxxxx 98/8/XX; |
|
b) |
„kombinací látky x xxxx xxxxxxxxx xxxxxxxxx xx xxxxxxxx xxxxxxxx“ xx xxxxxx kombinace xxxxx x xxxx xxxxxxxxx uvedená x xxxxxxx XX, xxxxx xxxxxxx xxxx xxxxxxxx:
|
|
x) |
„účastníkem“ xx xxxxxx xxxxx, která xxxxxxxxxx xxxxxx x xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxxx, xxxxx odpovídá xxxxxxxxxx podle xx. 17 xxxx. 5 xxxxxx nařízení, xxxx xxxxxx jménem xxxx tato xxxxxx xxxx xxxxxxxx předloženo; |
|
x) |
„xxxxxxxxxx xxxxxxxxxx orgánem“ xx xxxxxx příslušný orgán xxxxxxxxx xxxxx xxxxxxxxx x příloze XX xxxxxx nařízení, xxxxxx x xxxxxxx s článkem 81 xxxxxxxx (XX) x. 528/2012. |
XXXXXXXX 2
POSTUP XXXXXXXXX XXXXXXXXXXX
Xxxxxx 3
Žádost x xxxxxxxxx xxxx xxxxxxxx xx xxxxxxx X xxxxxxxx (XX) č. 528/2012
1.&xxxx;&xxxx;&xxxx;Xxxxxx x&xxxx;xxxxxxxxx xx xxxxxxxx do přílohy I nařízení (XX) x.&xxxx;528/2012 může xxxxx xxxxx xxxxxxxx, x xxxxx oznámení xxxxx xxxxxxxx k xxxxxx, xx xxxxxxxx xxxxxxxxxx podle xx.&xxxx;17 xxxx.&xxxx;5 xxxxxx xxxxxxxx.
Xxxxx xx xxxxxx xxxx xxxxxxxx do přílohy X&xxxx;xxxxxxxx (XX) x.&xxxx;528/2012, může xx xxxxx xxxxx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 xxxxxxx xxxxxxx.
2.&xxxx;&xxxx;&xxxx;Xxxxxxx uvedené v odstavci 1 se xxxxxxxx xxxxxxxx xx&xxxx;xxxx let xx xxxxxxxxxx x&xxxx;xxxxxxx x požadavky podle xx.&xxxx;17 odst. 5.
Xxxxxx 4
Xxxxxxx žádostí
1. Agentura xxxxxxxxx účastníka x xxxxxxxx splatném podle xxxxxxxxxxx xxxxxxxx Xxxxxx (XX) x. 564/2013 (7) x xxxxxxx xxxxxx, xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx 30 dnů. X xxxx xxxxxxxxxxx informuje xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxx.
2. Xx xxxxxxxx xxxxxxxx splatných xxxxx xxxxxxxxxxx xxxxxxxx (XX) x. 564/2013 xxxxxx xxxxxxxx žádost x xxxxxxxxx x xxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxx, xxxxxxx uvede datum xxxxxxx žádosti x xxxx xxxxxxxxx identifikační kód.
3. Xxxxx xxxxxxxxxxx xxxxxxxx podle xxxxxxxx 1 xxxxxx xxxxxx xxx xxxxx xxxxxxx xxxxxxxxxx v xxxxxxx x xxxxxxx 77 nařízení (XX) x. 528/2012.
4. Xxxxxxxxx příslušný xxxxx informuje xxxxxxxxx x xxxxxxxx splatném xxxxx xx. 80 xxxx. 2 xxxxxxxx (XX) x. 528/2012 xx 30 xxx xxxx, co agentura xxxxxxx xxxxxx, a xxxxxxx xxxxxx, xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx 30 xxx. X xxxx xxxxxxxxxxx informuje účastníka x agenturu.
Xxxxxx 5
Xxxxxxxxx xxxxxxx x xxxxxxxxx xxxx xxxxxxxx xx kategorie 6 xxxxxxx X xxxxxxxx (EU) x. 528/2012
1. Xxxxx agentura xxxxxx xxxxx xx. 4 xxxx. 2 xxxxxx x xxxxxxxxx xxxx zařazení xx xxxxxxxxx 6 xxxxxxx X xxxxxxxx (XX) x. 528/2012, xxxxx xxxxxxxx xxxxx xxxxxxxxxx x xxxxxxx s čl. 6 xxxx. 1 a 2 xxxxxxxxx nařízení, x xxx xxxxxxxx xxxxxxxx xxxxx xx. 4 xxxx. 4, hodnotící xxxxxxxxx orgán xxxxxx xxxxxxx xx 30 xxx xx xxxxxxxxx poplatků.
2. Xxxxx xxxxxxxxx příslušný xxxxx xxxxxxx xx xxxxxxxxx dokumentaci xxxxx xxxxxxxx (ES) x. 1451/2007, xxxxx xx xxxxx nebyla uznána xxxx xxxxx xxxxx xxxxxx 13 xxxxxxxxx xxxxxxxx, potvrdí xxxxxxxxx xxxxxxxxx orgán žádost xxxxxxxxxx do 3. xxxxx 2015.
3. X případech xxxxxxxxx x xxxxxxxxxx 1 x 2 xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx xxxxxxx xxx xxxxxxxxxxxx předložených xxxxx xxxx xxxxxxxxxx.
4. Pokud hodnotící xxxxxxxxx xxxxx xxxxxx, xx žádost xx xxxxxxx, xxxxx xxxxxxxxxxx, xxxx doplňující informace xxxx x xxxxxxxxx xxxxxxx nutné, x x xxxxxxxxxx xxxxxx xxxxxxxxx stanoví xxxxxxxxxx xxxxx. Xxxx xxxxx xxxxx xxxxxxxxxx 90 xxx.
Rozhodne-li xxxxxxxxx xxxxxxxxx xxxxx, xx předložené doplňující xxxxxxxxx xxxxxxxxx ke xxxxxxx požadavků uvedených x xxxxxxxx 2, xxxxxxx žádost xx 30 dnů xx xxxxxxxx doplňujících informací.
Xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxx xx stanovené xxxxx xxxxxxxxxx, hodnotící xxxxxxxxx xxxxx xxxxxx zamítne x xxxxxxxxx x xxxx xxxxxxxxxxx účastníka x xxxxxxxx. V xxxxxx případech se xxxxx poplatky xxxxxxxxx x xxxxxxx x xx. 80 xxxx. 1 x 2 xxxxxxxx (XX) x. 528/2012.
Xxx xxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxx účastníka, xxxxxxxx x xxxxx xxxxxxxxx xxxxxx x xxxxx xxxxx xxxxxx xxxxxxxxx.
Xxxxxx 6
Xxxxxxxxx xxxxxxx
1. Xxxxx xxxxxx xx použije, xxxxx xxxxx xxxxxxx x xxxxxx xxxxxxxx:
|
x) |
je-li xxxxxx xxxxxxxxx xxxxx xxxxxx 5; |
|
x) |
xxxxx hodnotící xxxxxxxxx xxxxx uznal xxxxxxxxxxx xxxx xxxxxx xxxxx xxxxxx 13 xxxxxxxx (XX) x. 1451/2007, ale xxxxx xxxxxxxxxxx Xxxxxx xxxxxx xxxxxxxxxxx orgánu podle xx. 14 odst. 4 xxxxxxxxx xxxxxxxx; |
|
x) |
xxxxx xxxxxxxx xxxxxxx xxxxxx o xxxxxxxx xx xxxxxxxxx 1, 2, 3, 4 xxxx 5 přílohy I nařízení (XX) x. 528/2012 podle xx. 4 odst. 2 a xxx xxxxxxxx poplatek xxxxx xx. 4 xxxx. 4. |
2. Xxxxxxxxx xxxxxxxxx orgán xxxxxxxx xxxxxx podle článků 4 x 5 xxxxxxxx (XX) č. 528/2012 a xxxxxxxx xxx veškeré xxxxxx xx xxxxxx požadavků xx údaje xxxxxxxxxx x xxxxxxx x xx. 6 odst. 3 uvedeného nařízení x xxxxx hodnotící xxxxxx x xxxxxx xxxxx xxxxxxxxx xxxxxxxx.
3. Xxxxx xxxxxxx kombinaci látky x typu xxxxxxxxx xxxxxxxxx několik účastníků, xxxxxxxxx xxxxxxxxx příslušný xxxxx xxxxx xxxxx xxxxxxxxx xxxxxx. Xxxxxxxxx xxxxxx x xxxxxx xxxxx x xxxxx x xxxxxx xxxx, xxxxx toho, xx xxxxxxx xxxxxxx:
|
x) |
365 xxx xx xxxxxxxxx xxxxxxxxx uvedeném x xxxx. 1 xxxx. x), xxxxxx xxxxxxxx xxxxxxxx x xxxx. 1 písm. b) xxxx xxxxxxxxx xxxxxxxx xxxxxxxxx x xxxx. 1 písm. c) x dotyčné kombinace xxxxx x xxxx xxxxxxxxx; |
|
b) |
xx xxxxx xxxxxxxxx x xxxxxxx XXX. |
4. Xxxx xxx, než xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxx xxx závěry xxxxxxxx, xxxxxx xxxxxxxxxxx xxxxx xx 30 xxx k xxxxxxxxx xxxxxx x k xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx. Xxxxxxxxx příslušný xxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxx x xxxxxxxxx xxxx xxxxx xxxxxxxxx.
5. Xxxxx se xxxxx, že xxxx x xxxxxxxxx xxxxx xxxxxxxxxx informace, hodnotící xxxxxxxxx xxxxx účastníka xxxxx, xxx xxxx xxxxxxxxx xx stanovené xxxxx xxxxxxxxx, a xxxxxxxxx x xxx xxxxxxxx.
Xxxxx 365 xxx xxxxxxx x xxxxxxxx 3 se xxxxxxx xx xxxx xxx xxx xxxxxxxx požadavku xx xxx xxxxxxxx xxxxxxxxx. Pokud xx xxxx odůvodněno xxxxxxx xxxxxxxxxxxx xxxxx nebo xxxxxxxxxxx okolnostmi, přerušení xxxxxxxxxx následující xxxxx:
|
x) |
365 xxx x xxxxxxx, že xx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxx, xxxxx xxxxxx xxxxxx x xxxxx xxxxxxxx 98/8/XX xxxx x xxxxx xxxxxxx xxxxxxxxxxx xxx xxxxxxxxxxx xxxxxxx směrnice; |
|
b) |
180 xxx xx xxxxx xxxxxxxxx xxxxxxxxx. |
6. Xxxxx xxxxxxxxx příslušný xxxxx xxxxxx, že xxxxxxxx xxxxx xxxxxxx xxxxxx xxxx nebo zvířat xxxx xxxxxxxxx prostředí xxxxxxxxxxx x xxxxxxxxxxxxx xxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxxxxx stejné xxxx xxxxxxxx účinné xxxxx, xxx xxxxx zdokumentuje x xxxxxxx x xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxx XX xxxx 3 přílohy XX nařízení Xxxxxxxxxx xxxxxxxxxx a Xxxx (XX) x. 1907/2006 (8) x xxxxxx xx xx xxxxx xxxxxx.
7. X xxxxxxx potřeby xx xxxxxxxxx hodnocení xxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxx zbytečného xxxxxxx a nejpozději xxx xxxxxxxxxx hodnotící xxxxxx xxxxx odstavce 3:
|
x) |
předloží xxxxx agentuře xxxxx xx. 37 xxxx. 1 nařízení (XX) č. 1272/2008, xxxxxxxx xx xxxxxxx, že je xxxxxxx xxxxx x xxxxxxxx xxxxxxxxx x xx. 36 odst. 1 xxxxxxxxx xxxxxxxx, xxx xxxx xxxxxxxx xxxxxx x xxxxx 3 přílohy VI xxxxxxxxx nařízení; |
|
b) |
xxxxxxxxxx x xxxxxxxxx, xxxxx xx xxxxxxx, xx xxxxx z kritérií čl. 5 xxxx. 1 xxxx. x) xxxx x) nařízení (XX) x. 528/2012 xxxx xxxxxxxx xx. 10 odst. 1 xxxx. x) xxxxxxxxx xxxxxxxx xxxx xxxxxxx, xxx xxxxxx xxxxxxxx řešeny x xxxxxxx XXX xxxxxxxx (ES) x. 1907/2006 nebo v seznamu xxxxxxxx x xx. 59 xxxx. 1 xxxxxxxxx nařízení. |
Xxxxxx 7
Xxxxxxxxxx xxxxxxxx
1. Xxxxx xxxxxx xx xxxxxxx, xxxxx xxxxx některá x xxxxxx xxxxxxxx:
|
x) |
xxxxx hodnotící xxxxxxxxx xxxxx předložil xxxxxxxxx xxxxxx xxxxx xx. 6 xxxx. 2 a xxxxxxxx předložil xxxxx xxxx xxxxxxx konzultaci xxxxx xx. 6 xxxx. 7; |
|
b) |
xxxxx xxxx předložena Komisi xxxxxx xxxxxxxxxxx orgánu xxxxx xx. 14 xxxx. 4 xxxxxxxx (XX) č. 1451/2007, xxx hodnotící xxxxxx xxxxx xxxxxxxxxxxx Xxxxx xxxxx xxx biocidní xxxxxxxxx xxxxx xx. 15 xxxx. 4 xxxxxxxxx xxxxxxxx. |
2. Po xxxxxxx zprávy xxxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxx x xxxx přípravku xxxx xxxx xxxxxxxx xx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 xxxxxxx X xxxxxxxx (EU) č. 528/2012, xxxxxxxx xxxxxx, x xxxxxxx xx xxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxx.
Xxxxxxxx xxxxxx xxxxxxxx xxxxxxxxxx v jedné z těchto xxxx, podle xxxx, xx xxxxxxx později:
|
x) |
xx xxx xxxxxx po xxxxxxx zprávy; |
|
b) |
xx lhůtě xxxxxxxxx v příloze XXX. |
Agentura xxxxxxxx xxxxxxxxxx Xxxxxx xx 270 dnů xx xxxxxxxx xxxxxxxx.
Xxxxxx 8
Účinné látky, xxxxx xx mají xxxxxxxx
1. Xxx přípravě svého xxxxxxxxxx xxxxx xx. 7 xxxx. 2 xxxxxxxx xxxxxxx, xxx účinná xxxxx xxxxxxx xxxxxxx x xxxxxxxx xxxxxxxxx x xx. 10 odst. 1 xxxxxxxx (EU) x. 528/2012, x xxxx xxxxxx xxxxx xx xxxx xxxxxxxxxx.
2. Xxxx xxxx xxxxxxx xxxxxx 66 x 67 xxxxxxxx (XX) x. 528/2012, xxxxx než xxxxxxxx předloží xxx xxxxxxxxxx Komisi, xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxx, xxxxx xx xxxx xxxxxxxx, během xxxxxxxxx 60 xxx; v xxxx xxxx xxxxx xxxxxxxxxx xxxxx strany xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxx informací x xxxxxxxxxx xxxxxxxxx. Xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx zohlední x xxxxxxxxx xxxx xxxxxxxx xxxxx stanoviska.
3. Pokud xx účinná látka xxxxxxxxx x xxxxxxx xxxxx x xxxxxxxx xxxxxxxxxxx x xx. 10 xxxx. 1 xxxxxxxx (XX) x. 528/2012, xxxx xxx xxxxxxxx za látku, xxxxx se xx xxxxxxxx, v nařízení xxxxxxxx x xxxxxxx x xx. 89 xxxx. 1 xxxxxx pododstavcem xxxxxxxxx xxxxxxxx.
Xxxxxx 9
Rozhodnutí Komise
Xx xxxxxxxx stanoviska xxxxxxxx xxxxx xx. 7 odst. 2 Xxxxxx xxx zbytečného xxxxxxxx xxxxxxxx xxxxx xxxxxxxxxx xxx přijetí xxxxx xx. 89 odst. 1, xxxx xxxxxxxx xxxxx xx. 28 xxxx. 1 xxxxxxxx (XX) x. 528/2012.
XXXXXXXX 3
ZMĚNY PRVKŮ XXXXXXXX XXXXXXXX
Xxxxxx 10
Připojení xxxx nahrazení účastníků xx vzájemné dohodě
1. Roli xxxxxxxxx xx xxxxx xx xxxxxxxx dohodě xxxx stávajícím účastníkem x potenciálním xxxxxxxxxx xxxxxxx nebo sdílet xx xxxxxxxxxxx, že xx xxxxxxxxxxx účastník xxxxx xxxxxxxxx xx xx xxxxxxx xxxxx xxxxxxxxxx nebo uvedené xxxxxxxxxx účastníkem.
2. Oznámení xxx xxxxx xxxxxx xxxxxx xxxxxxxxxxx agentuře xxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx xxx xxxxxxxx přípravky xxxxxxxxx x xxxxxx 71 xxxxxxxx (XX) x. 528/2012 (dále jen „xxxxxxxx“) a oznámení musí xxxxxxxxx všechna xxxxxxxxx xxxxxxxx x xxxxxxxx.
3.&xxxx;&xxxx;&xxxx;Xx xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxx podle xxxxxxxx 2 xxxxxxxx xxxxxxxxxxx xxxxxxxxx v rejstříku xxxxxxxx xx xxxxxxxxxx účastníka.
4. Osoba xxxxxxx na území Xxxx, xxxxx xxxxxxxx roli xxxxxxxxx xxxx xx xxxxxxxxx k xxxxxxxxxxx xxxxx xxxxxx článku, xx pro xxxxx xxxxxx 95 xxxxxxxx (XX) x.&xxxx;528/2012 považována xx osobu, xxxxx xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx x xxxxxxxx x xxxxxxxxxxx.
Xxxxxx 11
Odstoupení xxxxxxxxx
1. Xx xx za xx, xx xxxxxxxx xxxxxxxxx x xxxxxx xx xxxxxxx kombinace xxxxx x xxxx xxxxxxxxx v programu xxxxxxxx, v xxxxxx xxxxxxxxx:
|
x) |
xxxxx xxxxxxxxxx xxxxxxxx xxxx hodnotící xxxxxxxxx xxxxx xxxxxxxxxxxxxxx rejstříku x xxxx xxxxxx xxxxxxxxx; |
|
x) |
xxxxx nepředložil xxxxxx xx xxxxx uvedené x xx. 3 odst. 2; |
|
x) |
pokud xxxx xxxxxx xxxx zamítnuta xxxxx xx. 4 xxxx. 1, xx. 4 odst. 4 nebo xx. 5 odst. 4; |
|
d) |
pokud nepředložil xxxxxxxxxx xxxxxxxxx xx xxxxxxx xxxxxxxxx x xx. 6 xxxx. 5; |
|
x) |
xxxxx xxxxx nezaplatil xxxxxxxx hodnotícímu xxxxxxxxxxx xxxxxx xxxx agentuře. |
2. Xxxxxxxxxx xx xxxxxxxx xx xxxxxxxxx xxxx, xxxxx x xxxx xxxxxxx xx xxxx, kdy xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx zprávu xxxxxxxxxxx orgánu xxxxx xx. 6 xxxx. 4 tohoto xxxxxxxx.
Xxxxxx 12
Důsledky xxxxxxxx xxxxxxxxxx
1. Xxxxx je x xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx orgán, xxx nikoli xxxxxxxx, xxxxxxxxx ji xxxxxxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxx odkladu xxxxxxxxxxxxxxx xxxxxxxxx.
2. Xxxxx je x xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxx, aktualizuje xxxxxxxxx x xxxxxxxxx týkající xx xxxxxxxxxx účastníka.
3. Xxxxx x xxxxxxxx přezkumu včas xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxx kombinaci xxxxx x xxxx xxxxxxxxx x xxxxx xxxx xxxx xxxxxxxxx pro uvedenou xxxxxxxxx xxxxx převzata, xxxxxxxxx x tom xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx Xxxxxx.
Xxxxxx 13
Xxxx xxxxxxxx xxxxxxxxx látek
1. Xxxxx hodnocení xxxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx závěry xxxxxxxx xx látky, xxx xxxx xxxxxxx x xxxxxxx XX, xxxxxxxxx xxxxxxxxx xxxxx po xxxxxxxxxx x xxxxxxxx xxxxxxxxxx xxxxxxx xxxxx xxxxxxxx xxxxx. Xxxxxxxxx xxxxxxxxx xxxxx x xxx informuje xxxxxxxx.
2. Xxxxxxxx x xxxxxxxxx xxxxxxxxxxx xxxxxxxxx týkající se xxxxxxxx xxxxx.
Xxxxxx 14
Převzetí xxxx xxxxxxxxx
1. Xxxxxxxx xxxxxxxx xxxxxxxxx xxxxx k xxxxxxxx xxxx účastníka xxx xxxxxxxxx xxxxx a typu xxxxxxxxx, xxxxx nastane xxxxx x xxxxxx případů:
|
a) |
xxxxx xxxxxxx xxxxxxxxx podporující xxxxx xxxxxxxxx xxxxx x xxxx přípravku xxxx xxxxxxxxxx xxxxx xxxxxx 11 x xxxxxx xxxx účastníka xxx xxxxx kombinaci xxxxxx xxxxxxx převzata; |
|
b) |
xx xxxxxxx xxxx xxxxxxxx xxxxx xxxxxx 13; x xxxxx případě xx výzva xxxx xxxxx xx xxxxx, xx xxxxxx xx vztahuje xxxxxxxxx identita v příloze II, xxx xxxxxxx xxxx xxxxxxxx látky. |
2. Xx xxxxxxxx xxxxxx xxx xxx zveřejnění xxxxx xxxxxxxx 1 xxxx xxxxxxxxx osoba xxxxxxxxx oznámení pro xxxxxxxxx podle článku 17.
3. Xx xxxxxxxx xxxxxx xx xxxx xxxxxx tohoto nařízení x xxxxxxxx xxxx xxxxxxxxx xxxxx xxxxxxx xxxxxxxxx xxxxx a typu přípravku xxxxxxxxx xx části 2 xxxxxxx XX xxxxx xxxxxx 17.
Xxxxxx 15
Xxxxxxxxx látky x typu xxxxxxxxx xxxxxxxxx xxx xxxxxxxx xx programu xxxxxxxx
Xxxxx xxxxxxxx xxxxxxxxx, xxxxx xxxxx xx xxxxxxx xxxxxxxxxx xxxxxxxx (XX) x. 528/2012 a xx xxxxxx na trh, xxxxxxx ze xxxxxxxxx xxxxxx xxxxx, jež xxxx xxxxxxxxx xxx xxxxxxxx xx programu xxxxxxxx xxx xxxxx xxx xxxxxxxxx x xxxx zařazena xx xxxxxxx I uvedeného xxxxxxxx, xxxx xxxxx xxxxxxxx xxxx xx x xx xxxxxx, xx xxxxxxx xxxxx xxxxxxxxx pro xxxxxxxx xx xxxxxxxx xxxxxxxx xxx xxxxxxxxx xxx xxxxxxxxx xx xxxxxxx xxxxxxxxx x xxxxxx xxxxxx:
|
x) |
xxxxx xxxxxxxxx výrobek xx xxx xx xxxxxxxxx xx xxxxxx xxxx xxxxxxx doporučení xxxxxx Xxxxxx xxxx xxxxxxxxxx xxxxxxx jmenovaným v souladu x xxxxxxx 26 xxxxxxxx 98/8/XX xxxx článkem 81 xxxxxxxx (XX) x. 528/2012, xxxxx xx základě xxxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxx xxxxxxx xxxxxx xx doporučení x xxxxxxxxxxx, že výrobek xxx xxxxx x xxxxxxxxxx směrnice 98/8/XX xxxx xxxxxxxx (XX) č. 528/2012, nebo xx byl xxxxxxxxx xxx přípravku xxxxxx x xxxxxxxxx, xxx xxxxx byla xxxxxx xxxxx oznámena, a xxxxx jsou uvedené xxxxxx či xxxxxxxxxx xxxxxxxx xxxxxxxxxxx x xxxxxxxxxx přijatém xxxxx xx. 3 odst. 3 xxxxxxxx (XX) č. 528/2012 xxxx x xxxxxx, závazných xxxxxxxx xxxxxxxxxxxx Xxxxxx; |
|
b) |
látka xxxxxxxxx xxxxxxxx pro xxxxxxxxx a krmiva xxxxxxxxx x xxxxxx 6 xxxxxxxx (XX) x. 1451/2007; |
|
x) |
biocidní xxxxxxxxx xxxxx podle xxxxxxxx (XX) č. 528/2012 x xxxxxxxxx xxxx xxxxxxxxx, xxx xxxx xxxx xxxxx xxxxxxxx 98/8/XX, x xxxxxxxx xxxxx xxxxxxxxxx xxxxxx xxxx xxxxxxxxx x xxxxxxxx xxxxx zařazenou xx xxxxxxxx xxxxxxxx xxx xxxxxxx xxx přípravku, xxx xxxxxx xxx nový. |
Xxxxxx 16
Xxxxxxxxxx o xxxxx na xxxxxxxx
1. Xxxxxxxxxx x xxxxx xxxxxxx látku, xxxxx je xxxxxxxxx xxx xxxxxxxx do programu xxxxxxxx podle článku 15, xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx kterákoli osoba, xxx xx zájem xxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx, jednomu x xxxxxxxxxxxxx xxxxxxxx:
|
x) |
Xxxxxx xxxxxxxxxx dvanáct xxxxxx xx xxxxxxxxxx rozhodnutí xxxx xxxxxx uvedených x xx. 15 xxxx. x); |
|
x) |
agentuře xxxxxxxxxx 30. října 2015 x xxxxxxxxx uvedených x xx. 15 xxxx. x); |
|
x) |
Komisi xxxxxxxxxx 30. xxxxx 2015 x případech xxxxxxxxx x xx. 15 xxxx. x). |
2. Xxxxxxxxxx xxxx obsahovat xxxxxxxxxx kombinaci xxxxx x xxxx xxxxxxxxx. V případech xxxxxxxxx v čl. 15 xxxx. x) xxxx xxxxxxxxxx xxxxxxxxx opodstatněné xxxxxxxxxx, x xxxx xxxxxxx, xx jsou xxxxxxx xxxxxxx xxxxxxxx v xxx uvedené.
3. Pokud xxxx xxxxxxxxxx xxxxxxx x xxxxxxx xxxxxxxx x xx. 15 xxxx. x) xxxx x) x Xxxxxx xxxxxxx xx xxxxxxxxxx x xxxxxxxxx státy x závěru, xx xxxxxxxx 6 xxxx xxxxxxxxxx, x xxxxxxxx, xx xxxx xxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxx x xx. 15 xxxx. x), xxxxxxx x xxx xxxxxxxx.
4. Xxxxx bylo prohlášení xxxxxxx x xxxxxxx xxxxxxxx x xx. 15 písm. x) xxxx xxxxx Xxxxxx xxxxxxxxxxx agenturu xxxxx xxxxxxxx 3, zveřejní agentura xxxx informaci xxxxxxxxxxxxxx xxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxx látky x xxxx xxxxxxxxx. Pro xxxxx xxxxxx xxxxxxxx xx xxxxxxxxxx xxxxx xx. 3x xxxx. 3 třetího xxxxxxxxxxx xxxxxxxx (ES) č. 1451/2007 xxxxxxxx za xxxxxxxxxx xxxxx xxxxxx xxxxxxxx.
5. Xxxxxxxxx xxxxx, xxxxx xx xxxxx xxxxxxx xxxxxxxxx xxxxx a xxxx xxxxxxxxx, tak může xxxxxx xxxxx xxxxxx 17 xx xxxxx měsíců xxx dne zveřejnění xxxxx odstavce 4.
6. X xxxxxxxxx xxxxxxxxx v xx. 15 xxxx. x) a c) xx xxxxxxxxx látky x xxxx xxxxxxxxx xxxxxxxx xx xxxxxxxxx účastníkem x xxxx xxxxxxxxx x xxxxxxx xxxxxxxx, pokud jsou xxxxxxx xxxx podmínky:
|
x) |
xxxxxxxxx xxxxxx xxxxx xx xxx zařazena do programu xxxxxxxx; |
|
x) |
xxxxxxxxxxx xxxxxxxxxx hodnotícímu xxxxxxxxx státu xxx xxxxxxxxxx účinnou látku xxx xxxxxxxx xxxxxxx xxxxx, které jsou xxxxxxxx pro xxxxxxxxx xxxx přípravku; |
|
x) |
xxxxxxxx, který xxxxxxxxx dotyčnou dokumentaci, xxxxx, že xx xxxxx x xxxxxxx xxxx xxxxxxxxx xxxxx x xxxx přípravku. |
Xxxxxx 17
Xxxxxx xxxxxxxx
1. Oznámení xxxxx čl. 14 xxxx. 2 x 3 xxxx xx. 16 odst. 5 se xxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx.
2. Xxxxxxxx musí být xxxxxxxxxx xx xxxxxxx XXXXXX. Xxxx xxxxxxxxx xxxxx uvedené x xxxxxxx X.
3. Xxxxx xxxx x xxxxxxx XX pro dotyčnou xxxxxxx xxxxx uveden xxxxxxxxx příslušný xxxxx, xxxxxxxxx oznamovatel xxxxxxxx x xxxxx jím xxxxxxxxx xxxxxxxxxxx orgánu, xxxxx xx xxxxxxxx x xxxxxxx x xxxxxxx 81 xxxxxxxx (XX) x. 528/2012, x xxxxxxxx xxxxxxx xxxxxxxxx dokládající, xx xxxxxxxxx xxxxx xxxxxxxx x xxx, xx dokumentaci xxxxxxx.
4. Xx obdržení xxxxxxxx x xxx xxxxxxx xxxxxxxx Xxxxxx x xxxxxxxxxxxx informuje x xxxxxxxxxx xxxxxxxxx xxxxx nařízení (XX) x. 564/2013. Xxxxxxxx xxxxxxxxxxx xxxxxxxx poplatky xx 30 xxx xx přijetí uvedené xxxxxxxxx, agentura xxxxxxxx xxxxxxx a xxxxxxx x xxx oznamovatele x Xxxxxx.
5. Xx uhrazení xxxxxxxx agentura xx 30 dnů xxxxx, xxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx x xxxxxxxx 2. Xxxxx xxxxxxxx xxxxx požadavkům xxxxxxxxxx, xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxx x xxxxx 30 xxx, xxx xxx xxxxxxxx xxxxxxx nebo xxxxxxx. Xx xxxxxxxx xxxx 30xxxxx lhůty xxxxxxxx xx 30 dnů xxx prohlásí, xx xxxxxxxx xxxxxxxx požadavkům xxxxxxxx 2, xxxx xxxxxxxx xxxxxxx, x xxx xxxxxxxxxx xxxxx xxxxxxxxxxxx x Xxxxxx.
6. V xxxxxxx s xxxxxxx 77 xxxxxxxx (XX) x. 528/2012 xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxx 4 nebo 5 xxxxx xxxxxxx xxxxxxxxxx.
7. Xxxxx oznámení xxxxxxxx xxxxxxxxxx xxxxx xxxxxxxx 5:
|
x) |
x xxxxxxx, xx xxxx xxxxxxxx předloženo xxxxx xx. 14 odst. 2 nebo 3, xxxxxxxx neprodleně xxxxxxxxxxx informace x xxxxxxxxx týkající xx xxxxxxxxxx účastníka x xxxxxxxx identity xxxxx; |
|
x) |
x xxxxxxx, xx xxxxxxxx xxxx xxxxxxxxxx xxxxx čl. 16 xxxx. 5, agentura xxxxxxxxxx xxxxxxxxx Komisi, xx xxxxxxxxxx xxxx xxxxxxxx. |
Xxxxxx 18
Zařazení xx xxxxxxxx xxxxxxxx
Xxxxx je xxxxxxxxx látky x xxxx xxxxxxxxx xxxxxxxxxx xx xxxxxxxxx x xxxxxxx x xx. 16 xxxx. 6 nebo xxxxx xxxxxxxx xxxxxxxxx Xxxxxx x xxxxxxxx požadavků x souladu x xx. 17 xxxx. 7 písm. b), xxxxxx Xxxxxx kombinaci látky x xxxx xxxxxxxxx do xxxxxxxx xxxxxxxx.
Xxxxxx 19
Informace x xxxxxxx, xxxxx xxxxxx xxxxxx podporovány v xxxxx xxxxxxxx přezkumu
Xxxxx xxxxxx xx xxxxx xxxxxxxxx x xx. 16 xxxx. 5 obdrženo xxxxx xxxxxxxx xxxx xxxxx byla oznámení xxxxxxx xx zmíněném xxxxxx xxxxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx xx. 17 odst. 4 xxxx 5, xxxxxxxx o tom xxxxxxxxx xxxxxxx státy xxxxxxxxxxxxxxx xxxxxxxxx x xxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxx.
Xxxxxx 20
Rozhodnutí Xxxxxx x xxxxxxx, xxxxx xxxxxx nadále podporovány x xxxxx programu xxxxxxxx
Xxxxxx připraví xxxxx xxxxxxxxxx x xxxxxxxxxxx xxxxx čl. 89 odst. 1 xxxxxxx xxxxxxxxxxx xxxxxxxx (XX) č. 528/2012 v těchto xxxxxxxxx:
|
x) |
xxxxx xxxxxxxx xxxxxxxxx Xxxxxx x xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx xx. 12 xxxx. 3 xxxxxx xxxxxxxx; |
|
b) |
pokud xxxxx osoba xxxxxxxx xxxxxxxx xx xxxxxxx stanovených x xx. 14 xxxx. 2 xxxx 3 tohoto xxxxxxxx xxxx pokud xxxx xxxxxxxx předloženo x xxxxxxxxx xxxxx čl. 17 xxxx. 4 xxxx 5; |
|
c) |
pokud xxxx xxxxxxxx xxxxxxxxxx ve lhůtě xxxxxxxxx x xx. 14 xxxx. 2 xxxx 3 xxxxxx xxxxxxxx a byly xxxxxxxx xxxxxxxxx xxxxx xx. 17 xxxx. 5 xxxxxx xxxxxxxx, xxx identita xxxxx x xxxxxxxx xxxxxxxx pouze xxxx xxxxxxxxx xxxxxxxx x xxxxxxx XX xxxxxx nařízení. |
X xxxxxxx xxxxxxxx x xxxxxx xxxxxxxxxxx xxxx. c) xx xxxxx xxxxxxxxxx x xxxxxxxxxxx xxxxxxxx xx xxxxxx xxxxx, xx xxxxxx xx xxxxxxxx xxxxxxxxx xxxxxxxx v příloze II xxxxxx xxxxxxxx, xxxxx xxxxxx xxxxxxxx nebo jakékoli xxxxxxxxxx x xxxxxxxxx.
XXXXXXXX 4
XXXXXXXXX OPATŘENÍ
Článek 21
Xxxxxxxxx xxxxxxxx pro xxxxx xxxxxxx v článku 15
1. Členský xxxx xxxx xxxxxxxxxx x&xxxx;xxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxx nebo xxxxx xxxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxx xx stávající xxxxxx xxxxx xxxxxxx x xx. 15 xxxx. b) x x), tuto xxxxx xxxxxxxx xxxx x xx xxxxxx. V xxxxxx případech:
|
a) |
nesmí být xxxxxxxx xxxxxxxxx nadále xxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxx xx&xxxx;24 xxxxxx po xxxx xxxxxx xxxxxx xxxxxxxx x&xxxx;xxxxxxxx; |
|
x) |
xxxxxxxxx xxxxxx xxxxxxxxxx přípravku xxxxx xxx dále xxxxxxxxx xx&xxxx;30 měsíců xx xxx xxxxxx tohoto xxxxxxxx x&xxxx;xxxxxxxx. |
2.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx xxxxxxxxxx v uplatňování xxxxx xxxxxxxxxxx systému xxxx xxxxx xxxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxx xx xxxxxxxxx xxxxxx xxxxx xxxxxxx v xx. 15 xxxx. x), tuto xxxxx xxxxxxxx xxxx x xx xxxxxx. X xxxxxx případech:
|
a) |
nesmí xxx xxxxxxxx xxxxxxxxx xxxxxx xxxxxxx xx&xxxx;xxx s účinkem xx&xxxx;24 měsíců po xx x dále xxxxxxxxx xxxxxxxx, xxxxx xxxxxxx později:
|
|
b) |
stávající xxxxxx xxxxxxxxxx přípravku xxxxx být xxxx xxxxxxxxx do 30 xxxxxx xx xx x xxxx xxxxxxxxx událostí, xxxxx xxxxxxx xxxxxxx:
|
3.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx xxxxxxxxxx v uplatňování xxxxx xxxxxxxxxxx systému nebo xxxxx xxxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxx xx xxxxxxxxx xxxxxx xxxxx xxxxxxxxxx agenturou xxxxx xx. 16 xxxx. 4 xxx xxxxxxxxx xxx výrobku, tuto xxxxx obsahuje xxxx x ní xxxxxx. X xxxxxx xxxxxxxxx:
|
x) |
xxxxx xxx biocidní přípravek xxxxxx xxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxx xx&xxxx;xxxxxxxx xxxxxx xx xxxx, kdy xxxxxxxx xxxxxxxx elektronické xxxxxxxxxx podle článku 19 x |
|
x) |
xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxx xxx xxxx xxxxxxxxx xx&xxxx;xxxxxxxx měsíců xx xxxx xxxxxxxxx zveřejnění. |
Xxxxxx 22
Xxxxxxxx xxxxxxx
1. Aniž xx xxxxxx čl. 55 xxxx. 1 xxxxxxxx (EU) x. 528/2012, xx xxxxxxxx xxxxxx xx xxxx xxxxxxxxxx o neschválení xxxxxxxxx xxxxxx xxxxx, xxxxx xxxxxxx xxxx xxxxxxxx tuto xxxxxxxxx xxxxxxx xxxxx xx xxxxxxxxx x xxxxxx uvedených x xx. 5 xxxx. 2 prvním xxxxxxxxxxx xxxx. x) xxxx x) xxxxxxxx (EU) x. 528/2012, tento xxxxxxx xxxx xxxx předložit Xxxxxx xxxxxxxxxxx xxxxxx x xxxxxxxx xx xx. 89 xxxx. 2 xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx.
2. Xxxxxxxx xxxxxxx stát xxxxxxxx xxxxxxxxxxx xxxxxx xxxxxxxx xxxxxxxxxxxxxxx rejstříku. Xxxxx xxxxxx obsahuje xxxxxxx informace, xxxxxxxx xxxxxxx xxxx xxxx xxxxxxx xxxxxxxxx xxxxxxxxx xxxxx.
3. Xxxxxxxx xxxxxxxx xxxxxx xxxx případně xxxxxxxxxx xxxxx elektronickými xxxxxxxxxx. Xxxxxxx státy nebo xxxx xxxxx xxxxx xxxxx xxxxxxxxxx xx xxxxx 60 xxx xx xxxxxxxxxx.
4. Xx zvážení obdržených xxxxxxxxxx xxxx Komise xxxxxxx xxxxxxxx od čl. 89 xxxx. 2 xxxxxxx pododstavce xxxxxxxx (XX) č. 528/2012, xxxxx xxxxxx xxxxxx xxxxxxxx xxxxxxxxx, jež xxxxxxxxx x xxxx xxxxx, xxxxxxxx xx xxxx x ní xxxxxxxx, xx trh xxxxxxxxxx xxxxxxxxx státu x xxxxxxxx je x xxxxx xxxxxxxx státu v souladu x xxxxxxxxxxxxxx xxxxxxxx předpisy x x xxxxxxxx xxxxxxxx xxxxxxxx 5 a veškerých xxxxxxx xxxxxxxx uložených Komisí.
5. Xxxxxxx xxxx, xxxxx je xxxxxxxx odchylka:
|
a) |
xxxxxxx, xx xxxxx xxxxxxxxx bude omezeno xx xxxxxx xxxxxxx x xxxxxxx dobu, xxx xxxx xxxxxx podmínky xxxxxxxx 1; |
|
x) |
xxxxxx vhodná xxxxxxxx xx xxxxxxxx rizik, xxx xxxxxxxx minimalizaci xxxxxxxx xxxxxxx, xxxxxx xxxx xxxxxxxxx prostředí; |
|
c) |
xxxxxxx, xxx xx xxxxxxx xxxxxxxxxxxx xxxxxx xxxx aby xxxx včas před xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxx o schválení xxxxxx xxxxx x xxxxxxx xxxxxxx 7 xxxxxxxx (XX) x. 528/2012. |
XXXXXXXX 5
ZÁVĚREČNÁ USTANOVENÍ
Článek 23
Xxxxxxx
Xxxxxxx xx xxxxxxxx (XX) x. 1451/2007.
Odkazy xx zrušené nařízení xx xxxxxxxx xx xxxxxx na toto xxxxxxxx.
Xxxxxx 24
Xxxxx x xxxxxxxx
Xxxx xxxxxxxx xxxxxxxx x platnost dvacátým xxxx xx xxxxxxxxx x Úředním xxxxxxxx Xxxxxxxx xxxx.
Xxxx xxxxxxxx xx xxxxxxx x xxxxx xxxxxxx x přímo xxxxxxxxxx xx xxxxx xxxxxxxxx státech.
X Xxxxxxx xxx 4. srpna 2014.
Xx Xxxxxx
xxxxxxxx
Xxxx Manuel XXXXXXX
(1)&xxxx;&xxxx;Xx. xxxx. X 167, 27.6.2012, x. 1.
(2) Nařízení Xxxxxx (ES) x. 1451/2007 xx xxx 4. xxxxxxxx 2007 x druhé xxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxx x xx. 16 xxxx. 2 směrnice Evropského xxxxxxxxxx x Xxxx 98/8/XX x xxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx (Xx. xxxx. X 325, 11.12.2007, x. 3).
(3) Směrnice Xxxxxxxxxx xxxxxxxxxx x Xxxx 98/8/ES xx dne 16. xxxxx 1998 o xxxxxxx biocidních přípravků xx xxx (Xx. xxxx. X 123, 24.4.1998, x. 1).
(4) Rozsudek Xxxxxxxx xxxxx (xxxxxxx xxxxxx) xx xxx 1. xxxxxx 2012 (xxxxxx x xxxxxxxxxx x předběžné xxxxxx: Xxxxxxxxxxx Hamburg – Německo) – Xöxx XxxX proti Xxxxx GmbH (xxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx – xxxxxxxx 98/8/XX – xx. 2 xxxx. 1 xxxx. a) – xxxxx „biocidní xxxxxxxxx“ – xxxxxxxxx, který xxxxxxxxx vločkování xxxxxxxxxx xxxxxxxxx, xxxx xx xxxx, xxxxxxxx xxxx xxxxxxxxxxx), C-420/10.
(5) Prováděcí xxxxxxxx Xxxxxx (XX) x.&xxxx;88/2014 xx xxx 31.&xxxx;xxxxx 2014, xxxxxx xx xxxxxxx xxxxxx pro xxxxx xxxxxxx X&xxxx;xxxxxxxx Evropského xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;528/2012 x&xxxx;xxxxxxxx biocidních xxxxxxxxx xx xxx x&xxxx;xxxxxx xxxxxxxxx (Úř. xxxx. X 32, 1.2.2014, s. 3).
(6)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (ES) x. 1272/2008 ze xxx 16. xxxxxxxx 2008 x xxxxxxxxxxx, xxxxxxxxxx a xxxxxx xxxxx x xxxxx, x změně x xxxxxxx směrnic 67/548/XXX x 1999/45/XX x x xxxxx xxxxxxxx (XX) x. 1907/2006 (Xx. xxxx. L 353, 31.12.2008, x. 1).
(7)&xxxx;&xxxx;Xxxxxxxxx xxxxxxxx Xxxxxx (XX) č. 564/2013 ze xxx 18.&xxxx;xxxxxx 2013 x&xxxx;xxxxxxxxxx a platbách xxxxxxxxx Xxxxxxxx xxxxxxxx xxx xxxxxxxx látky xxxxx xxxxxxxx Xxxxxxxxxx parlamentu x&xxxx;Xxxx (XX) x.&xxxx;528/2012 x&xxxx;xxxxxxxx biocidních přípravků xx xxx a jejich xxxxxxxxx (Úř. věst. L 167, 19.6.2013, x. 17).
(8)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (ES) x. 1907/2006 xx xxx 18. prosince 2006 o xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxx látek, x xxxxxxx Xxxxxxxx xxxxxxxx xxx chemické xxxxx, x xxxxx xxxxxxxx 1999/45/XX a x xxxxxxx xxxxxxxx Xxxx (XXX) x.&xxxx;793/93, xxxxxxxx Komise (ES) x. 1488/94, směrnice Xxxx 76/769/XXX x xxxxxxx Xxxxxx 91/155/XXX, 93/67/XXX, 93/105/XX a 2000/21/XX (Xx. xxxx. X 396, 30.12.2006, x. 1).
XXXXXXX X
Xxxxxxxxx požadované xxx oznámení podle xxxxxx 17
Xxxxxxxx xxxxx xxxxxx 17 xxxxxxxx xxxx xxxxxxxxx:
|
1) |
xxxxx, xx xxxxx xx stávající účinnou xxxxxx xx xxxxxx xx. 3 xxxx. 1 písm. d) xxxxxxxx (XX) č. 528/2012; |
|
2) |
xxxxx x xxxx/xxxxxx xxxxxxxxx, na xxxxx/x xx oznámení xxxxxxxx; |
|
3) |
xxxxxxxxx x xxxxx studiích, xxxxx xxxx xxxxxx xxx účely xxxxxxx x xxxxxxxxx či zařazení xx xxxxxxx I nařízení (XX) x. 528/2012, xxxxx i očekávané xxxxx xxxxxx xxxxxxxxx; |
|
4) |
xxxxxxxxx xxxxxxx v xxxxxxxx
|
|
5) |
xxxxx xxxx xxxx xxxxxxxx xxxxxxx x xxxxxxx uvedeném x xx. 15 xxxx. x), xxxxx, že látka xxxx xx xxxx xxxx účinná xxxxx biocidního xxxxxxxxx xxxxxxxxxxx xx xxxxxxxxxxx typu xxxxxxxxx x xxx xxxxxxxx xxxx xxxxxxxxxx rozhodnutí xxxx pokynů xxxxxxxxx xx xxxxxxxx písmenu. |
XXXXXXX II
XXXXXXXXX XXXXX X XXXX XXXXXXXXX XXXXXXXX XX XXXXXXXX PŘEZKUMU DNE 4. XXXXX 2014
XXXX 1
Xxxxxxxxx xxxxxx látky x xxxx xxxxxxxxx xxxxxxxxxxx xx xxx 4. xxxxx 2014, s výjimkou xxxxxxxxxx xxxxxx xxxxxxxxxxxxx xxx xxxx, xxxxx xxxx výslovně xxxxxxx x xxxxxxxxx 1017 a 1019.
|
Číslo xxxxxxx |
Xxxxx xxxxx |
Xxxxxxx xxxx xxxxxxxxx |
Xxxxx XX |
Xxxxx XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
|
1 |
xxxxxxxxxxx |
XX |
200-001-8 |
50-00-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
6 |
5-{[2-(2-xxxxxxxxxxxx)xxxxxx]xxxxxx}-6- xxxxxx-1,3-xxxxxxxxxxx (xxxxxxxxxxxxxxxx/XXX) |
XX |
200-076-7 |
51-03-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
9 |
xxxxxxxx |
XX |
200-143-0 |
52-51-7 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
|
|
|
|
|
x |
|
29 |
xxxxxxxxxxx |
XX |
200-431-6 |
59-50-7 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
|
36 |
xxxxxxx |
XX |
200-578-6 |
64-17-5 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37 |
xxxxxxxx xxxxxxxx |
XX |
200-579-1 |
64-18-6 |
|
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
40 |
xxxxxx-2-xx |
XX |
200-661-7 |
67-63-0 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
43 |
xxxxxxxx xxxxxxxxxx |
XX |
200-712-3 |
69-72-7 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45 |
propan-1-ol |
XX |
200-746-9 |
71-23-8 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
52 |
xxxxxxxxxxx |
X |
200-849-9 |
75-21-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60 |
kyselina xxxxxxxxx |
XX |
201-069-1 |
77-92-9 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
69 |
xxxxxxxxx xxxxxxxx/2-xxxxxxxxxxxxxxx xxxxxxxx |
LT |
201-180-5 |
79-14-1 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
70 |
kyselina xxxxxxxxxxxx |
XX |
201-186-8 |
79-21-0 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
71 |
X-(+)-xxxxxx kyselina |
XX |
201-196-2 |
79-33-4 |
|
x |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
79 |
2-xxxxxxxxxxx-8,9-xxxxxxxxx-1,2,6,6x,12,12x-xxxxxxxxxxxxxxxxx[3,4-x]xxxx[2,3-x]xxxxxxx-6-xx (rotenon) |
XX |
201-501-9 |
83-79-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
85 |
xxxxxxxxx |
XX |
201-782-8 |
87-90-1 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
92 |
bifenyl-2-ol |
XX |
201-993-5 |
90-43-7 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
113 |
cinnamaldehyd/3-fenylprop-2-enal (xxxxxxxxxxxxx) |
XX |
203-213-9 |
104-55-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
117 |
xxxxxxxx |
XX |
203-377-1 |
106-24-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
122 |
xxxxxxx |
XX |
203-474-9 |
107-22-2 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
133 |
xxxx-2,4-xxxxxxx xxxxxxxx (kyselina xxxxxxx) |
XX |
203-768-7 |
110-44-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
136 |
xxxxxxxx (glutaraldehyd) |
XX |
203-856-5 |
111-30-8 |
|
x |
x |
x |
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
154 |
xxxxxxxxx |
N |
204-385-8 |
120-32-1 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
171 |
2-fenoxyethan-1-ol |
UK |
204-589-7 |
122-99-6 |
x |
x |
|
x |
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
172 |
xxxxxxxxxxxxxxx-xxxxxxx/1-xxxxxxxxxxxxxxxx-1-xxx-xxxxxxx |
XX |
204-593-9 |
123-03-5 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
179 |
oxid uhličitý |
XX |
204-696-9 |
124-38-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
180 |
(natrium-kakodylát) – xxxxxxx-xxxxxxxxxxxxxxx |
XX |
204-708-2 |
124-65-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
185 |
xxxxxxxxxxxxxx, xxxxx xxx (xxxxx sůl xxxxxxxxxxxxxxx – xxxxxxxxx X) – (N-chlor-4-methylbenzen-1-sulfonamid |
XX |
204-854-7 |
127-65-1 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
187 |
kalium-dimethyldithiokarbamát |
UK |
204-875-1 |
128-03-0 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
188 |
xxxxxxx-xxxxxxxxxxxxxxxxxxxxxx |
UK |
204-876-7 |
128-04-1 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
195 |
xxxxxxx-xxxxxxx-2-xxxx |
XX |
205-055-6 |
132-27-4 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
198 |
X-[(xxxxxxxxxxxxxx)xxxxxxxx]xxxxxxxx (xxxxxx) |
XX |
205-088-6 |
133-07-3 |
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
206 |
xxxxxx |
XX |
205-286-2 |
137-26-8 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
210 |
xxxxxx-xxxxxxx |
XX |
205-293-0 |
137-42-8 |
|
|
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (xxxxxxxxxxxx) |
ES |
205-725-8 |
148-79-8 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
235 |
xxxxxx |
XX |
206-354-4 |
330-54-1 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
|
239 |
karbamonitril |
XX |
206-992-3 |
420-04-2 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
253 |
tetrahydro-3,5-dimethyl-1,3,5-thiadiazin-2-thion (xxxxxxx) |
XX |
208-576-7 |
533-74-4 |
|
|
|
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
279 |
X-[(xxxxxxxxxxxxxxxxxx)xxxxxxxx]-X′,X′-xxxxxxxx-X-(4-xxxxxxxxxxx)xxxxxxxxxx (xxxxxxxxxxxx) |
XX |
211-986-9 |
731-27-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
|
283 |
xxxxxxxxx |
XX |
212-950-5 |
886-50-0 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
288 |
X-[(xxxxxxxxxxxxxxxxxx)xxxxxxxx]-X-xxxxx-X′,X′-xxxxxxxxxxxxxxxx (xxxxxxxxxxxxx) |
XX |
214-118-7 |
1085-98-9 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
|
289 |
xxxxxxxxxxxx xxxxx |
XX |
214-183-1 |
1111-67-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
292 |
[(1,3-xxxxx-1,3,4,5,6,7-xxxxxxxxx-2X-xxxxxxxx-2-xx)xxxxxx]-xxxxx-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxx-xxxxxxxxxxxx) |
XX |
214-619-0 |
1166-46-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
958 |
xxxxxxxx xxxxxxxx/xxxxxxxxxxx vápno/hašené xxxxx |
XX |
215-137-3 |
1305-62-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
959 |
xxxx xxxxxxxx/xxxxx/xxxxxx xxxxx/xxxxxxxx xxxxx |
XX |
215-138-9 |
1305-78-8 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
306 |
xxxx xxxxx |
XX |
215-270-7 |
1317-39-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
315 |
butan-2-on-peroxid |
XX |
215-661-2 |
1338-23-4 |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
321 |
xxxxxxxxxxx |
UK |
217-129-5 |
1746-81-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
330 |
X-(3-xxxxxxxxxxx)-X-xxxxxxxxxxxxx-1,3-xxxxxx (xxxxxx) |
XX |
219-145-8 |
2372-82-9 |
|
x |
x |
x |
|
x |
|
x |
|
|
x |
x |
x |
|
|
|
|
|
|
336 |
X,X′-xxxxxxxx-2,2′-xxxxxxxxxxxxxxxxxxxxxx (XXXXX) |
XX |
219-768-5 |
2527-58-4 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
339 |
1,2-xxxxxxxxxxxxxxx-3(2X)-xx (BIT) |
XX |
220-120-9 |
2634-33-5 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
341 |
2-xxxxxxxxxxxxxxxxxxxxxxxxxx-3(2X)-xx (XXX) |
XX |
220-239-6 |
2682-20-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
346 |
natrium-dichlorisokyanurát xxxxxxxx |
XX |
220-767-7 |
51580-86-0 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
345 |
xxxxxxx-xxxxxxxxxxxxxxxxxx |
XX |
220-767-7 |
2893-78-9 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
348 |
xxxxx(xxxxxxxxx)xxxxxxxxxxxxxxx-xxxxx-xxxxxx (XXX) |
XX |
221-106-5 |
3006-10-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
354 |
xxxxxxxxx |
DK |
222-182-2 |
3380-34-5 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
359 |
(ethylendioxy)dimethanol (xxxxxxx xxxxxxxx xxxxxxxxxxxxxx x xxxxxxxxxxxxxxxx (XXXxxx)) |
PL |
222-720-6 |
3586-55-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
365 |
xxxxxxx-2-xxxxx-1-xxxx, sodná xxx (xxxxxxxxx xxxxx) |
XX |
223-296-5 |
3811-73-2 |
|
x |
x |
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
368 |
1-(3-chlorallyl)-3,5,7-triaza-1-azoniaadamantan-chlorid (XXXX) |
XX |
223-805-0 |
4080-31-3 |
|
|
|
|
|
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
377 |
1,3,5-xxxx(2-xxxxxxxxxxxx)xxxxxxxxx-1,3,5-xxxxxxx (XXX) |
XX |
225-208-0 |
4719-04-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
382 |
1,3,4,6-tetrakis(hydroxymethyl)hexahydroimidazo[4,5-d]imidazol-2,5-dion (TMAD) |
ES |
226-408-0 |
5395-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
387 |
dimorfolinomethan (XXX) |
XX |
227-062-3 |
5625-90-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
392 |
xxxxxxxx-xxxxxxxxxxxx |
XX |
228-652-3 |
6317-18-6 |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
393 |
1,3-xxx(xxxxxxxxxxxxx)-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (DMDMH) |
PL |
229-222-8 |
6440-58-0 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
397 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx (XXXX) |
IT |
230-525-2 |
7173-51-5 |
x |
x |
x |
x |
|
x |
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
401 |
xxxxxxx |
SE |
231-131-3 |
7440-22-4 |
|
x |
|
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
403 |
xxx |
XX |
231-159-6 |
7440-50-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
405 |
xxxx xxxxxxxx |
XX |
231-195-2 |
7446-09-5 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
424 |
xxxxxx xxxxx |
XX |
231-599-9 |
7647-15-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
432 |
chlornan xxxxx |
IT |
231-668-3 |
7681-52-9 |
x |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
434 |
xxxxxxxxxxxx |
XX |
231-711-6 |
7696-12-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
439 |
peroxid xxxxxx |
XX |
231-765-0 |
7722-84-1 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
444 |
7x-xxxxxxxxxxxx-1X,3X,5X-xxxxxxx[3,4-x]xxxxxx (XXXX) |
XX |
231-810-4 |
7747-35-5 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
450 |
xxxxxxxx xxxxxxxx |
XX |
231-853-9 |
7761-88-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
453 |
peroxodisíran xxxxx |
XX |
231-892-1 |
7775-27-1 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
455 |
xxxxxxxx xxxxxxxx |
IT |
231-908-7 |
7778-54-3 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
457 |
chlor |
IT |
231-959-5 |
7782-50-5 |
|
x |
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
458 |
síran amonný |
XX |
231-984-1 |
7783-20-2 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
473 |
pyrethriny x xxxxxxxxxxx |
XX |
232-319-8 |
8003-34-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
491 |
oxid chloričitý |
XX |
233-162-8 |
10049-04-4 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
494 |
2,2-dibrom-2-kyanacetamid (XXXXX) |
XX |
233-539-7 |
10222-01-2 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
501 |
xxxxxxxxxxx |
XX |
234-232-0 |
10605-21-7 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
515 |
xxxxxx amonný |
SE |
235-183-8 |
12124-97-9 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
522 |
zink-1-oxo-1λ5-pyridin-2-thiolát |
XX |
236-671-3 |
13463-41-7 |
|
x |
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
x |
|
|
524 |
xxxxxxxxxxxxxxx-xxxxxxxxxxxxxxxx |
XX |
237-030-0 |
13590-97-1 |
|
|
|
|
|
x |
|
|
|
|
x |
|
|
|
|
|
|
|
|
526 |
xxxxxx-xxxxxxx-2-xxxx |
XX |
237-243-9 |
13707-65-8 |
|
|
|
|
|
x |
|
|
x |
x |
|
|
x |
|
|
|
|
|
|
529 |
brommonochlorid |
NL |
237-601-4 |
13863-41-7 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
531 |
(xxxxxxxxx)xxxxxxxx |
XX |
238-588-8 |
14548-60-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
534 |
bis(1-hydroxypyridin-2(1H)-thionato-O,S)měďnatý xxxxxxx (xxxxxxxxx xxxx) |
SE |
238-984-0 |
14915-37-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
541 |
xxxxxxx-4-xxxxx-3-xxxxxxxxxxxxx |
FR |
239-825-8 |
15733-22-9 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
|
550 |
5,5′-xxx(4-xxxxxxxxxx)-1,1′-(xxxxx-1,6-xxxx)xxx(xxxxxxxx)-xxx(x-xxxxxxxx) (XXXX) |
XX |
242-354-0 |
18472-51-0 |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
554 |
4-[(xxxxxxxxxxx)xxxxxxxx]-1-xxxxxxxxxxxx |
UK |
243-468-3 |
20018-09-1 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
559 |
[(xxxxxxxxxxxx-2-xx)xxxxxxxx]xxxxxx-xxxxxxxxxx (XXXXX) |
X |
244-445-0 |
21564-17-0 |
|
|
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
562 |
[2-xxxxxx-4-xxx-3-(xxxx-2-xx-1-xx)xxxxxxxxx-2-xx-1-xx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxxx) |
EL |
245-387-9 |
23031-36-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
563 |
xxxxxx-(X,X)-xxxx-2,4-xxxxxxx (sorbát xxxxxxxx) |
XX |
246-376-1 |
24634-61-5 |
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
566 |
α, α′,α′′-xxxxxxxxxxxxxxxxxx-1,3,5-xxxxxxx-1,3,5-xxxxxxxxxx (XXX) |
AT |
246-764-0 |
25254-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
571 |
2-oktyltetrahydroisothiazol-3-on (XXX) |
XX |
247-761-7 |
26530-20-1 |
|
|
|
|
|
x |
x |
|
x |
x |
x |
|
x |
|
|
|
|
|
|
577 |
xxxxxxxx(xxxxxxxxx)[3-(xxxxxxxxxxxxxxx)xxxxxx]xxxxxxx-xxxxxxx |
ES |
248-595-8 |
27668-52-6 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
578 |
N2-terc-butyl-N4-cyklopropyl-6-(methylsulfanyl)-1,3,5-triazin-2,4-diamin (xxxxxxxx) |
XX |
248-872-3 |
28159-98-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
588 |
xxxxxxxxx-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (XXXXX/xxxxxxxxxxxxxxxxxxxxxxxxxx) |
XX |
251-171-5 |
32718-18-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
590 |
3-(4-isopropylfenyl)-1,1-dimethylmočovina/isoproturon |
DE |
251-835-4 |
34123-59-6 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
|
597 |
1-[2-(allyloxy)-2-(2,4-dichlorfenyl)ethyl]imidazol (imazalil) |
XX |
252-615-0 |
35554-44-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
599 |
S-[(6-chlor-2-oxooxazolo[4,5-b]pyridin-3(2H)-yl)methyl]-O,O-dimethyl-fosforothioát (xxxxxxxxxxx) |
XX |
252-626-0 |
35575-96-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
600 |
2-xxxx-2-(xxxxxxxxxx)xxxxxxxxxxxxxx (XXXXX) |
CZ |
252-681-0 |
35691-65-7 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
961 |
xxxx xxxxxxxx-xxxxxxxxx/xxxxxxxxxxx xxxxx |
XX |
253-425-0 |
37247-91-9 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
962 |
xxxxxxxx xxxxxxxx-xxxxxxxxx/xxxxxxxxxxx xxxxxxxxxxx xxxxx |
XX |
254-454-1 |
39445-23-3 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
606 |
[(3-xxxxxxxxxxx)xxxxxxxxxx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (cyfenothrin) |
XX |
254-484-5 |
39515-40-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
608 |
dimethyl(tetradecyl)[3-(trimethoxysilyl)propyl]amonium-chlorid |
XX |
255-451-8 |
41591-87-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
609 |
xxx- x xxxxx-x-xxxxxxx-3,8-xxxx (xxxx) (citriodiol) |
XX |
255-953-7 |
42822-86-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
614 |
(XX)-α-xxxxx-3-xxxxxxxxxxxx-(1XX)-xxx,xxxxx-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
257-842-9 |
52315-07-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (permethrin) |
IE |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
618 |
[1-ethynyl-2-methylpent-2-en-1-yl]-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyklopropan-1-karboxylát (xxxxxxxxxx) |
XX |
259-154-4 |
54406-48-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
619 |
3-jodprop-2-yn-1-yl-N-butylkarbamát (XXXX) |
XX |
259-627-5 |
55406-53-6 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
620 |
xxxxxxxx(xxxxxxxxxxxxx)xxxxxxxxx-xxxxxx (2:1) (XXXX) |
XX |
259-709-0 |
55566-30-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
628 |
(±)-1-{[2-(2,4-xxxxxxxxxxxx)-4-xxxxxx- 1,3-xxxxxxxx-2-xx]xxxxxx}-1X-1,2,4-xxxxxxx (xxxxxxxxxxxx) |
XX |
262-104-4 |
60207-90-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
635 |
xxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxx xxxxx (XXXXX/XXXX) |
XX |
263-038-9 |
61789-18-2 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
648 |
4,5-xxxxxxx-2-xxxxxxxxxxxxxxx-3(2X)-xx (4,5-xxxxxxx- 2-xxxxx-2X-xxxxxxxxxx-3-xx (DCOIT)) |
X |
264-843-8 |
64359-81-5 |
|
|
|
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
|
649 |
1-(2-chlorbenzyl)-3-[(trifluormethoxy)fenyl]močovina (xxxxxxxxxxx) |
XX |
264-980-3 |
64628-44-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
656 |
xxx(5-xxxxxxxxxxxxxxxx-3-xx)xxxxxx (xxxxxxxxxx/XXX) |
XX |
266-235-8 |
66204-44-2 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
657 |
6-(xxxxxxxxxxxxxxxx)-1,3,5-xxxxxxx-2,4-xxxxxx (cyromazin) |
XX |
266-257-8 |
66215-27-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
666 |
[(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxx) |
DE |
269-855-7 |
68359-37-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
667 |
alkyl(C12-18)dimethylbenzylammoniumchlorid (XXXXX (X12-18)) |
XX |
269-919-4 |
68391-01-5 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
671 |
alkyl(C12-16)dimethylbenzylammoniumchlorid (XXXXX/XXX (X12-X16)) |
XX |
270-325-2 |
68424-85-1 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
673 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx (XXXX) (X8-10) |
XX |
270-331-5 |
68424-95-3 |
x |
x |
x |
x |
|
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
|
690 |
xxxxx(X12-X18)xxxxxx(xxxxxxxx)xxxxxxxx xxxx 1,1-xxxxx-1λ-1,2-xxxxxxxxxxxxxxx-3(2X)-xxx (XXXXX) |
XX |
273-545-7 |
68989-01-5 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
691 |
xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx |
AT |
274-357-8 |
70161-44-3 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
692 |
alkyl(C10-C16)dimethylaminoxidy |
XX |
274-687-2 |
70592-80-2 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
693 |
xxx(xxxxxxxxxxx)-xxx(xxxxx) xxxxxxxxxxxxx |
XX |
274-778-7 |
70693-62-8 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
701 |
xxxxxxxxx-xxxxxxxxxxxxxxxx xxxxxxxxxx (XXXX) |
XX |
279-013-0 |
84665-66-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1015 |
xxxxxxx, Xxxxxxxxxxx xxxxxx, výtažek |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
724 |
xxxxx(X12-X14)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX (X12-X14)) |
XX |
287-089-1 |
85409-22-9 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
725 |
alkyl(C12-C14)ethylbenzylammoniumchlorid (XXXXXX (X12-X14)) |
XX |
287-090-7 |
85409-23-0 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
731 |
xxxxxxxxx xxxxxxxxxxxx, Xxxxxxxxxxxxx xxxxxxxxxxxxxxxx, xxxxxxx |
ES |
289-699-3 |
89997-63-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
744 |
xxxxxxxxx xxxxxx, Xxxxxxxxx xxxxxxx, xxxxxxx/xxxxxxxxxxx xxxx |
XX |
294-470-6 |
91722-69-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
776 |
1-[3,5-xxxxxxx-4-(1,1,2,2-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxxxx)xxxxxxxx (xxxxxxxxxxxx) |
PT |
401-400-1 |
86479-06-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
779 |
xxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx a X-xxxxx(X12-X14)xxxxxx-1,2-xxxxxxx (glukoprotamin) |
XX |
403-950-8 |
164907-72-6 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
785 |
6-xxxxxxxxxxxxxxxxxxxxxxx kyselina (XXX) |
XX |
410-850-8 |
128275-31-0 |
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
791 |
2-xxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx (XXXX) |
XX |
420-590-7 |
4299-07-4 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
792 |
xxxxxxx xxxxxxxxxxxxxxxxxxx (XXXX) |
XX |
420-970-2 |
92047-76-2 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
811 |
xxxxxxxxxxxxxxxxxxx xxxxxxxx-xxxxx-xxxxxxxxxxx |
SE |
422-570-3 |
265647-11-8 |
x |
x |
|
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
794 |
xxx-xxxxx-2,2-(2-xxxxxxxxxxxx)xxxxxxxxx-1-xxxxxxxxxx (xxxxxxxx) |
XX |
423-210-8 |
119515-38-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
797 |
1-((Z)-3-chlorallyl)-3,5,7-triaza-1-azoniaadamantanchlorid (xxx-XXXX) |
XX |
426-020-3 |
51229-78-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
800 |
{[2,5-xxxxx-3-(xxxx-2-xx-1-xx)xxxxxxxxxxxx-1-xx]xxxxxx}-2,2-xxxxxxxx-3- (2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx- 1-xxxxxxxxxx (xxxx xxxxxxxxxxxxx) (xxxxxxxxxxx) |
UK |
428-790-6 |
72963-72-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
790 |
5-xxxxx-2-(4-xxxxxxxxxxx)xxxxx (XXXX) |
XX |
429-290-0 |
3380-30-1 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
807 |
(X)-1-[(2-xxxxxxxxxxxx-5-xx)xxxxxx]-3-xxxxxx-2-xxxxxxxxxxxxx (chlothianidin) |
XX |
433-460-1 |
210880-92-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
952 |
Xxxxxxxx sphaericus 2362, xxxx XXXX-1743 |
IT |
xxxxxxxxxxxxxxx |
143447-72-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
955 |
Xxxxxxxx xxxxxxxxxxxxx subsp. israelensis, xxxx SA3A |
XX |
xxxxxxxxxxxxxxx |
není xxxxxxxxxx |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
957 |
Bacillus xxxxxxxx |
XX |
xxxxxxxxxxxxxxx |
xxxx xxxxxxxxxx |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
928 |
5-xxxxx-2-xxxxxxxxxxxxxxxx-3(2X)-xx (Xxxxxx 247-500-7) a 2-methylisothiazol-3(2H)-on (Xxxxxx 220-239-6), xxxx (3:1) (směs XXXX/XXX) |
XX |
xxxx |
55965-84-9 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
939 |
xxxxxxx xxxxx (vyráběný xxxxxx xxxxxxxx xxxxxxx a xxxxxxxxx xxxxxxx xx xxxx) |
XX |
xxxx |
xxxx relevantní |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
813 |
peroxyoktanová xxxxxxxx |
FR |
xxxx xxxxxxxxxx |
33734-57-5 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1014 |
xxxxxxxx xxxxxx |
XX |
není relevantní |
xxxx xxxxxxxxxx |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxxxxxx) |
IE |
není xxxxxxxxxx |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
931 |
alkyltrimethylendiaminy, X-X12-14(xx xxxxx xxxxxx), xxxxxxxx xxxxxx x xxxxxxxxxxxx xxxxxxxxx (Xxxxxxxx 20) |
XX |
xxxx xxxxxxxxxx |
139734-65-9 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
152 |
produkty reakce 5,5-xxxxxxxxxxxxxxxxxx, 5-xxxxx-5-xxxxxxxxxxxxxxxx x xxxxxx x chlorem (XXXXX) |
XX |
xxxx k dispozici |
není x xxxxxxxxx |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
459 |
xxxxxxx xxxx xxxxx xxxxxxxxxxxx x chloridu stříbrného |
XX |
xxxx x xxxxxxxxx |
xxxx x xxxxxxxxx |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
|
777 |
xxxxxxx xxxxxxxx 5,5-xxxxxxxxxxxxxxxxxx, 5-xxxxx-5-xxxxxxxxxxxxxxxx s chlorem (XXXXX) |
XX |
xxxx x xxxxxxxxx |
není x xxxxxxxxx |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
810 |
xxxxxxxxxxxxxx xxxx s xxxxxxx xxxxxxx |
XX |
xxxx k dispozici |
308069-39-8 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
824 |
xxxxxxxx-xxxxxxxxx xxxxxx |
XX |
xxxx x xxxxxxxxx |
130328-20-0 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
1013 |
xxxxxxxx-xxxxxxx zeolit |
XX |
xxxx k dispozici |
130328-19-7 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
1017 |
xxxxxxx xxxxxxxxxxx xx oxidu xxxxxxxxxx (xxxx xxxxxxxxxxxx xx xxxxx xxxxxxxxxx xxxxxxxx x xxxxxxxxxx xxxxxxxxx xx xxxxxxxxxx) |
XX |
není k dispozici |
není x xxxxxxxxx |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
1019 |
xxxx xxxxxxxxx (xxxx xxxxxxxxxxxx tvořený xxxxxxxx x xxxxxxxxxx) |
XX |
xxxx x xxxxxxxxx |
68909-20-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
831 |
xxxxxxxxx |
XX |
přípravek na xxxxxxx rostlin |
61790-53-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
854 |
(XX)-3-xxxx-2-xxxxx-4-xxxxxxxxxxxx-2-xxxx-(1X,3X;1X,3X)-2,2-xxxxxxx-3-(2-xxxxxxxxx-1-xxxx)-xxxxxxxxxxxxxxxxxxxxx (směs 4 xxxxxxx 1X xxxxx, 1X: 1X xxxxx, 1X: 1R xxx, 1R: 1R xxx, 1X 4:4:1:1) (x-xxxxxxxxx) |
XX |
xxxxxxxxx xx ochranu xxxxxxx |
231937-89-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
855 |
(XX)-3-xxxxx-2-xxxxxx-4-xxxxxxxxxxxx-2-xx-1-xx-(1X,3X)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (směs 2 xxxxxxxxxxxxx) (esbiothrin) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
260359-57-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
848 |
X-[(6-xxxxx-3-xxxxxxx)xxxxxx]-X′-xxxx-X-xxxxxxxxxxxxxxxxxxx (acetamiprid) |
BE |
xxxxxxxxx xx ochranu rostlin |
160430-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
835 |
xxxxxxxxxxxx/(X)-(3-xxxxxxxxxxx)xxxxxxxxxx-(X)-2-(4-xxxxxxxxxx)-3-xxxxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
xxxxxxxxx xx ochranu xxxxxxx |
66230-04-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
836 |
[(3-xxxxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (α-xxxxxxxxxxxx) |
XX |
přípravek xx xxxxxxx xxxxxxx |
67375-30-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
843 |
4-xxxx-2-(4-xxxxxxxxxx)-1-(xxxxxxxxxxxx)-5-(xxxxxxxxxxxxxx)xxxxxx-3-xxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
přípravek xx ochranu xxxxxxx |
122453-73-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
859 |
polymer X-xxxxxxxxxxxxxxxxx(XXXXXX 204-697-4) x (xxxxxxxxxxx)xxxxxxxx (XXXXXX 203-439-8)/xxxxxxxxx xxxxxxxxx chlorid xxxxxx (XX Xxxxxxx) |
XX |
xxxxxxx |
25988-97-0 |
|
x |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
863 |
xxxx(xxxxxxxx-1,5-xxxxxxxxx-1,6-xxxx) (XXXX) |
XX |
xxxxxxx |
27083-27-8/32289-58-0 |
x |
x |
x |
x |
x |
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
|
868 |
xxxx(xxxxxxxx-1,5-xxxxxxxxx-1,6-xxxx-xxxxxxxxxxxx) |
XX |
polymer |
91403-50-8 |
x |
x |
x |
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
869 |
α-[2-(xxxxxxxxxxxxxxxxxxx)xxxxx]-ω-[xxxxxxxxxxx(xxxxxxxxxx)-xxxxxxxxx] (Xxxxxx 26) |
XX |
xxxxxxx |
94667-33-1 |
|
x |
|
x |
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
872 |
N-didecyl-N-dipolyethoxyammonium-borát/ α, α ′-(xxxxxxxxxxxxx)xxx[ω-xxxxxxxxx(xxxxxxxxxx)]-xxx xx (polymerický xxxxxx) |
XX |
xxxxxxx |
214710-34-6 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
XXXX 2
Xxxxxxxxx xxxxxx xxxxx x xxxx xxxxxxxxx nepodporované xx xxx 4. xxxxx 2014
Xxxx xxxx xxxx přílohy xxxxxxxx
|
— |
kombinace xxxxx x xxxx přípravku xxxxxxx x xxxxxxx xxxx, xxxxxx xxxxxxxxxx xxxxxxxxx, |
|
— |
jakékoli xxxxxxxxx xxxxx kombinací xxxxx x xxxx přípravku xxxxxxxxx x xxxxxxx x xxxxx 1, xxxxx xxxx, které xxxx uvedeny x xxxxxxx, x |
|
— |
xxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxxxx xx 4. xxxxx 2014, x xxxxxxxx xxxx, xxxxx xxxx výslovně xxxxxxxxx. |
Kombinace xxxxx x xxxx xxxxxxxxx x xxxxxxxxxxxxx zařazené xx xxxx části xxxxx předmětem rozhodnutí x neschválení xxxxx xxxxxx 20, xxxxxxxx xxxxx xxxxx xxxxxx xxxxxxxx xx xxxxxxxx měsíců xx xxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxx xx. 14 odst. 3 xxxx xxxxx xx xxxxxx xxxxxxxx xxxxxxxxx xxxxx xx. 17 xxxx. 4 nebo 5.
|
Xxxxx xxxxxxx |
Xxxxx xxxxx |
Členský xxxx xxxxxxxxx |
Xxxxx ES |
Xxxxx XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
|
1021 |
1,3-xxxxxxx-5,5-xxxxxxxxxxxxxxxxx (xxxx xxxxxxxxxx xxxxx xxxxxxx 152) |
XX |
204-258-7 |
118-52-5 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
166 |
benzyl(hexadecyl)dimethylamonium-chlorid (xxx xxxxxxx 948) |
|
204-526-3 |
122-18-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
167 |
benzyl(dimethyl)oktadecylamonium-chlorid (xxx xxxxxxx 948) |
|
204-527-9 |
122-19-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
213 |
xxxxxx(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxxx (xxx položka 948) |
|
205-351-5 |
139-07-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
214 |
xxxxxx(xxxxxxxx)xxxxxxxxxxxxxxxxx-xxxxxxx (xxx položka 948) |
|
205-352-0 |
139-08-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
205-725-8 |
148-79-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
331 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxx (xxx položka 949) |
|
219-234-1 |
2390-68-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
384 |
xxxxxxxx(xxxxxxx)xxxxxxx-xxxxxxx (xxx xxxxxxx 949) |
|
226-901-0 |
5538-94-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
399 |
xxxxxx(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxx (xxx položka 948) |
|
230-698-4 |
7281-04-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
401 |
xxxxxxx |
XX |
231-131-3 |
7440-22-4 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
418 |
xxxx křemičitý xxxxxxx |
XX |
231-545-4 |
7631-86-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
449 |
xxxxx xxxxxxx |
XX |
231-847-6 |
7758-98-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1016 |
xxxxxxx xxxxxxxx |
XX |
232-033-3 |
7783-90-6 |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
|
554 |
4-[(xxxxxxxxxxx)xxxxxxxx]-1-xxxxxxxxxxxx |
XX |
243-468-3 |
20018-09-1 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
587 |
decyl(dimethyl)oktylamonium-chlorid (viz xxxxxxx 949) |
|
251-035-5 |
32426-11-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
601 |
benzyldimethyl(oktadec-9-en-1-yl)amonium-chlorid (xxx xxxxxxx 948) |
|
253-363-4 |
37139-99-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (xxxxxxxxxx) |
XX |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
637 |
xxxxx(xxxxxx)xxxxxxxxxxxxxxx-xxxxxxxx (xxxxx xxxxxxx od xxxxxxxx xxxxxxx xxxxxxxxxx xxxxx) (viz xxxxxxx 948) |
|
263-080-8 |
61789-71-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
638 |
xxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx odvozen xx xxxxxxxx kyselin xxxxxxxxxx xxxxx) (xxx xxxxxxx 949) |
|
263-087-6 |
61789-77-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
639 |
dialkyl(dimethyl)amonium-chloridy (xxxxx xxxxxxx xx hydrogenovaných xxxxxxxx xxxxxxx loje) (xxx položka 949) |
|
263-090-2 |
61789-80-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
647 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx položka 948) |
|
264-151-6 |
63449-41-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
668 |
xxxxxxx(X6-X12)xxxxxxxxxxxxxxx-xxxxxxxx (xxx položka 949) |
|
269-925-7 |
68391-06-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
670 |
xxxxx(X8-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx položka 948) |
|
270-324-7 |
68424-84-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
689 |
xxxxx(X10-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx položka 948) |
|
273-544-1 |
68989-00-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
692 |
alkyl(C10-C16)dimethylaminoxidy |
XX |
274-687-2 |
70592-80-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
697 |
xxxxxxx(X8-X18)xxxxxxxxxxxxxx-xxxxxxxx (xxx položka 949) |
|
277-453-8 |
73398-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1000 |
dihydrogen-bis(monoperoxyftalato)magnesát xxxxxxxxxx |
XX |
279-013-0 |
14915-85-4 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
998 |
xxxxxxx xxxxxxx xxxx xxx x xxxxx xxxxxxxx Xxxxxxxxxxx indica xxxxxxxxxxx xxxxx x xxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
741 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
293-522-5 |
91080-29-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1020 |
1,3-xxxxxxx-5-xxxxx-5-xxxxxxxxxxxxxxxxxx-2,4-xxxx (xxxx xxxxxxxxxx xxxxx položky 777) |
NL |
401-570-7 |
89415-87-2 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
778 |
1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-3-[(1X-1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxx-3-xx (xxxxxxxxxxx) |
XX |
403-640-2 |
107534-96-3 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
805 |
xxxxxxx xxxxxxx xxxxxxxx-xxxxxxx, xxxxxxxx-xxxxxxxxx a xxxxxxxx-xxxxxxxxx x xxxxxxxxx xxxxxx (xxxxxxxx) |
XX |
432-790-1 |
xxxx relevantní |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
923 |
xxxxx(xxxxxx)xxxxxxxxxxxxxxx-xxxxxxx/xxxxxxxxxxxx-xxxxxxx (viz xxxxxxx 948) |
|
xxxx |
8001-54-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
949 |
(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx xxxx -xxxxxx-xxxxxxx) (xxxxxx (X6-X18) nasycené a xxxxxxxxxx, xxxxxxxx od xxxxxxxx kyselin xxxx, xxxxxxxxxx oleje x xxxxxxxx oleje) (DDAC) |
IT |
xxxx xxxxx xxxxxxxxx x xxxxxxx XXXXXX |
xxxx relevantní |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
950 |
xxxxxxxxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx xxxx -methyl-sulfáty) (xxxxxx (X8-X18) nasycené x xxxxxxxxxx, xxxxxxxx xx xxxxxxxx xxxxxxx xxxx, kokosového oleje x xxxxxxxx xxxxx) (XXXX) |
XX |
xxxx xxxxx xxxxxxxxx x xxxxxxx EINECS |
není xxxxxxxxxx |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
948 |
xxxxxx(xxxxx)xxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx xxxx -xxxxxxxxx) (alkyly (C8-C22) xxxxxxxx x xxxxxxxxxx, xxxxxxxx xx mastných xxxxxxx xxxx, kokosového xxxxx x xxxxxxxx xxxxx) (XXX) |
XX |
xxxx xxxxx xxxxxxxxx x xxxxxxx EINECS |
není xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxxxxxx) |
IE |
není xxxxxxxxxx |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
1001 |
xxxxx(X12-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxx než xxxxx xxxxxxxxx pod položku 671) |
XX |
xxxx xxxxxxxxxx |
není xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
x |
|
1002 |
xxxxx(X12-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx(xxxx xxx xxxxx xxxxxxxxx xxx xxxxxxx 667) |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
1003 |
alkyl(C12-C18)(ethylbenzyl)dimethylamonium- xxxxxxxx (xxxx xxx xxxxx xxxxxxxxx xxx xxxxxxx 725) |
XX |
xxxx xxxxxxxxxx |
xxxx relevantní |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
1005 |
xxxxx(X12-X14)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxx než xxxxx xxxxxxxxx pod položku 724) |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
1006 |
fosforečnanové xxxx xxxxxxxxxx stříbro, xxxxx, xxxxxx a xxx |
XX |
xxxx relevantní |
398477-47-9 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
1009 |
xxxxxxx(X8-X10)xxxxxxxxxxxxxx-xxxxxxxx (xxxx xxx látka xxxxxxxxx xxx xxxxxxx 673) |
XX |
není xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
x |
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
|
1011 |
xxxxx(xxxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx xxxxxxx od mastných xxxxxxx xxxxxxxxxx oleje) (xxxx xxx xxxxx xxxxxxxxx pod položku 635) |
XX |
xxxx xxxxxxxxxx |
není xxxxxxxxxx |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
1012 |
xxxxxxxxxxxxxxxxx xxxxx, xxxxxxxx x xxxxxxxxx xxxxxxx/xxxxxxxx-xxxxxxxxx xxxxxx |
XX |
xxxx xxxxxxxxxx |
130328-20-0 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
598 |
(±)-1-(β-xxxxxxxx-2,4-xxxxxxxxxxxxxxxxx)xxxxxxxx (xxxxxxxx xxxxxxxxx) |
XX |
přípravek xx xxxxxxx xxxxxxx |
73790-28-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
XXXXXXX XXX
Xxxxx
|
Xxxx xxxxxxxxx |
Xxxxx pro xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx čl. 6 xxxx. 3 xxxx. x) |
Xxxxx pro zahájení xxxxxxxx xxxxxxxxxx xxxxx xx. 7 xxxx. 2 písm. b) |
|
8, 14, 16, 18, 19 x 21 |
31.12.2015 |
31.3.2016 |
|
3, 4 x 5 |
31.12.2016 |
31.3.2017 |
|
1 x 2 |
31.12.2018 |
31.3.2019 |
|
6 x 13 |
31.12.2019 |
31.3.2020 |
|
7, 9 a 10 |
31.12.2020 |
31.3.2021 |
|
11, 12, 15, 17, 20 a 22 |
31.12.2022 |
31.9.2023 |